Kenneth T. Mills

CIK: 0001652824

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (14.3%)

Position reduction

Option Exercises (M)3 (42.9%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)1 (14.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RGNX

REGENXBIO Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

RGNX
REGENXBIO Inc.
May 29, 2026
Award(A)
Direct
9.8K shares-
RGNX
REGENXBIO Inc.
Jan 27, 2026
Exercise(M)
Direct
225K shares at avg. $13.09$2.9M
RGNX
REGENXBIO Inc.
Jan 27, 2026
Tax Payment(F)
Direct
221.8K shares at avg. $13.41$3.0M
RGNX
REGENXBIO Inc.
May 30, 2025
Award(A)
Direct
7.8K shares-
RGNX
REGENXBIO Inc.
May 12, 2025
Exercise(M)
Direct
20.6K shares at avg. $3.76$77K
RGNX
REGENXBIO Inc.
May 12, 2025
Sale(S)
Direct
20.6K shares at avg. $7.91$163K
RGNX
REGENXBIO Inc.
Mar 27, 2025
Exercise(M)
Direct
30.8K shares at avg. $3.76$116K

		Type	Shares	Price		Ownership
May 29, 2026	RGNX REGENXBIO Inc.	Award(A)	9,807	-	$0	Direct
Jan 27, 2026	RGNX REGENXBIO Inc.	Exercise(M)	225,000	$13.09	$2,945,250	Direct
Jan 27, 2026	RGNX REGENXBIO Inc.	Tax Payment(F)	221,753	$13.41	$2,973,708	Direct
May 30, 2025	RGNX REGENXBIO Inc.	Award(A)	7,768	-	-	Direct
May 12, 2025	RGNX REGENXBIO Inc.	Exercise(M)	20,602	$3.76	$77,464	Direct
May 12, 2025	RGNX REGENXBIO Inc.	Sale(S)	20,602	$7.91	$163,046	Direct
Mar 27, 2025	RGNX REGENXBIO Inc.	Exercise(M)	30,752	$3.76	$115,628	Direct

1-7 of 7 transactions

About Mills Kenneth T.

Mills Kenneth T. (SEC CIK 0001652824) files insider reports with the SEC as Director of REGENXBIO Inc. (RGNX).

Signal8 holds 5 ownership filings by Mills Kenneth T., all Form 4s, filed between Mar 31, 2025 and Jun 2, 2026. Those filings report 7 transactions, from Mar 27, 2025 to May 29, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mills Kenneth T.'s filings is in ROCKVILLE, MD.

Recent filings by Mills Kenneth T.

May 29, 2026: Grant or award of RGNX shares (Form 4, code A).
Jan 27, 2026: Option exercise of RGNX shares (Form 4, code M).
Jan 27, 2026: Tax withholding of RGNX shares (Form 4, code F).
May 30, 2025: Grant or award of RGNX shares (Form 4, code A).
May 12, 2025: Option exercise of RGNX shares (Form 4, code M).

Other insiders filing for REGENXBIO Inc. (RGNX)

Malzahn Craig, Chief Technology Officer
Christmas Patrick J., Chief Strategy & Legal Officer
PAKOLA STEVE, Chief Medical Officer
Chan Mitchell, Chief Financial Officer
Ciongoli Gregory Austin, Director
Simpson Curran, Chief Executive Officer

How to read Form 4 transaction codes